EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments

Youjin Oh iD, Sung Mi Yoon, Jeeyeon Lee iD, Joo Hee Park, Soowon Lee, Timothy Hong, Liam Il-Young Chung iD, Sumedha Sudhaman, Timothy Riddell, Charuta C Palsuledesai iD, Michael Krainock, Minetta C Liu und 1 weitere

Thoracic Cancer · 2024-05 · 15 (13) · 1095-1102

DOI: 10.1111/1759-7714.15281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2024-04. Verfasst von Youjin Oh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA, Neoplasm, Residual, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for detection of minimal residual disease (MRD), monitoring treatment response, and early detection of recurrence in cancer patients. In this study, we explored the utility of ctDNA‐based MRD detection to predict recurrence in a real‐world cohort of primarily early‐stage non‐small cell lung cancer (NSCLC) patients treated with curative intent.

Methods

Longitudinal plasma samples were collected post curative‐intent treatment from 36 patients with stage I–IV NSCLC. A personalized, tumor‐informed assay was used to detect and quantify ctDNA in plasma samples.

Results

Of the 24 patients with plasma samples available during the MRD window (within 6 months of curative surgery and before adjuvant therapy), ctDNA was detectable in two patients. Patients with ctDNA‐positivity during the MRD window were 15 times more likely to recur compared to ctDNA‐negative patients (HR: 15.0, 95% CI: 1.0–253.0, p = 0.010). At any time post‐curative intent treatment, ctDNA‐positivity was associated with significantly poorer recurrence‐free survival compared to persistently ctDNA‐negative patients ( p < 0.0001).

Conclusion

Our real‐world data indicate that longitudinal, personalized, tumor‐informed ctDNA monitoring is a valuable tool in patients with NSCLC receiving curative treatment to identify patients at high risk for recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCirculating Tumor DNANeoplasm, ResidualLung NeoplasmsHumansMaleFemaleAgedMiddle AgedBiomarkers, TumorNeoplasm Recurrence, LocalPrecision MedicinePrognosisAged, 80 and overAdult

Stichwörter der Autor:innen

biomarkerctDNAlung cancermolecular residual diseaseprognosis

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Department of internal medicine, John H. Stroger Hospital of Cook County, Chicago, Illinois, USA.
  • North Central Bronx Hospital, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Kyungpook National University School of Medicine, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
  • Baylor University, Waco, Texas, USA.
  • Natera, Inc., Austin, Texas, USA.

ORCID-Profile: Youjin Oh, Jeeyeon Lee, Liam Il-Young Chung, Charuta C Palsuledesai, Young Kwang Chae

Zitieren

APA

Oh, Y., Yoon, S. M., Lee, J., Park, J. H., Lee, S., Hong, T., Chung, L. I., Sudhaman, S., Riddell, T., Palsuledesai, C. C., Krainock, M., Liu, M. C., & Chae, Y. K. (2024). Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments. Thoracic Cancer, 15(13), 1095-1102. https://doi.org/10.1111/1759-7714.15281

Vancouver

Oh Y, Yoon SM, Lee J, Park JH, Lee S, Hong T, et al. Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments. Thoracic Cancer. 2024;15(13):1095-1102. doi:10.1111/1759-7714.15281

BibTeX
@article{Oh2024,
  author = {Oh, Youjin and Yoon, Sung Mi and Lee, Jeeyeon and Park, Joo Hee and Lee, Soowon and Hong, Timothy and Chung, Liam Il-Young and Sudhaman, Sumedha and Riddell, Timothy and Palsuledesai, Charuta C and Krainock, Michael and Liu, Minetta C and Chae, Young Kwang},
  title = {Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments},
  journal = {Thoracic Cancer},
  year = {2024},
  volume = {15},
  number = {13},
  pages = {1095--1102},
  doi = {10.1111/1759-7714.15281}
}
Kostenlos starten →